为解决白藜芦醇(Res)因水溶性小、稳定性差、生物利用度低而在临床的应用受到限制的问题，将叶酸 -聚乙二醇 -脂质体(FA-PEG-Lip)、介孔碳纳米管(MCN)和 Res混合并超声处理，制备得到装载 Res的 FA-PEG-Lip包裹的 MCN(FA-PEG-Lip@MCN/Res)纳米体系。所获得的 FA-PEG-Lip@MCN/Res具有纳米级尺寸[宽：(80±10)nm；长：(600±100)nm]、负的表面电荷(-10.2 mV)、出色的载药量(131.59 mg/g MCN)、良好的溶液分散性和近红外(NIR)激光刺激 -响应释放能力等特点。由于叶酸受体介导的靶向运输， FA-PEG-Lip@MCN/Res纳米体系可以高特异性地将所运载的 Res转运到人乳腺癌细胞(MCF-7)。细胞增殖毒性试验表明，未装载药物的 FA-PEG-Lip@MCN其本身生物相容性良好，适于作为药物载体。一系列细胞水平及活体水平的肿瘤治疗试验证明，在 NIR激光照射下，该 FA-PEG-Lip@MCN/Res纳米体系表现出良好的化疗 /光热协同治疗作用，能够对肿瘤进行高效地杀伤。总而言之，该 FA-PEG-Lip@MCN/Res纳米体系能够同时实现提高 Res的水溶性、增强 Res的稳定性、延长 Res在小鼠体内的半衰期、叶酸受体靶向、 NIR激光刺激 -响应释放以及肿瘤协同治疗等诸多功能，有望进一步推动 Res在临床的应用。

Resveratrol (Res) is a promising molecule for.ghting cancer. However, the potential of the drug is immensely hindered by several limiting factors, including poor water solubility, limited chemical stability, and low bioavailability. In or-der to solve the above problems, we report a facile synthesis of a Res-loaded folate-terminated PEG-liposome (FA-PEG-Lip) coated mesoporous carbon nanotube (MCN) nanosystem (FA-PEG-Lip@MCN/Res) by simply sonicating Res and MCN in FA-PEG-Lip suspensions. The as-obtained FA-PEG-Lip@MCN/Res exhibits a nanoscale size [width: (80±10) nm, length: (600±100) nm], a negative surface potential (-10.2 mV), an excellent drug loading (131.59 mg/g MCN), good monodisper-sity and near infrared (NIR) laser stimulation-response release. Owing to folate receptor-mediated targeted delivery, the FA-PEG-Lip@MCN/Res nanosystem can deliver loaded Res to human breast cancer MCF-7 cells with high speci.city. The cell toxicity viability shows that unloaded FA-PEG-Lip@MCN has no cytotoxicity, confirming its suitability as a drug vehicle. In addition, a systematic in vitro and in vivo experiments demonstrated that, under NIR laser irradiation, the FA-PEG-Lip@ MCN/Res nanosystem exhibits highly e.cient chemotherapy/photothermal synergistic therapy. All in all, the FA-PEG-Lip@ MCN/Res nanosystem can simultaneously improve Res water solubility, enhance Res stability, extend plasma half-life of Res in mice, folate receptor targeting, NIR laser stimulation-response release, and synergistic tumor therapy, which may greatly promote the application of Res in clinical practice.